Aflatoxin B1, Hepatocellular carcinoma, Cirrhosis, This study aimed to assess the role of micro-ribonucleic acid-24 (microRNA-24) expression in patients with cirrhosis and hepatocellular carcinoma (HCC) who have experienced high levels of aflatoxin B1 (AFB1) exposure. Fifty HCC and 24 hepatic cirrhosis patients, in addition to 20 healthy control subjects were included in this study. Aflatoxin B1 was measured by enzyme-linked immunosorbent assay (ELISA) and microRNA-24 was detected using real-time polymerase chain reaction (real-time PCR). Both aflatoxin B1 levels and microRNA-24 expression were found to be significantly increased in all patient groups in comparison to controls, more so in the HCC than cirrhotic group (p<0.0001). A highly significant correlation was detected between levels of AFB1 and amount of microRNA-24 expressed in both patient groups relative to their control counterparts (p<0.0001). Receiver Operating Characteristic (ROC) curve performed to evaluate the ability of microRNA-24 to differentiate between HCC and cirrhosis showed that it had sensitivity of 80% and specificity of 63% at cutoff 1.3, which was highly significant (p<0.0001). Increased aflatoxin B1 levels detected in patients with cirrhosis and HCC further support previous studies evaluating the level of exposure of the Egyptian population to this carcinogen and support the critical role of aflatoxin B1 in the appearance of HCC. In addition, microRNA-24 expression levels demonstrated in both cirrhosis and HCC might be valuable for use as a noninvasive diagnostic tool for diagnosis of HCC.
Introduction 
Hepatocellular carcinoma is a potentially life-threatening affliction that constitutes over 90% of primary hepatic malignancy. This cancer is the sixth most common worldwide, accounting for a third of all cancer-related deaths (Jemal et al., 2011) . Over 80% of HCC sufferers occur in developing countries most commonly as a result of exposure to hepatitis B or C viruses (HBV or HCV) or ingestion of AFB1 that contaminate various crops, such as corn and peanuts, in hot humid climates. These two principal risk factors of HCC are predominantly found in highly endemic regions of Africa and Asia (Xia et al., 2013; Torre et al., 2015) .
Several studies have demonstrated excessively high levels of aflatoxin exposure to the Egyptian community. AFB1 is the most common aflatoxin, originating from the Aspergillusflavus and Aspergillusparasiticus mold species (Hamid et al., 2013) . Exaggerated concentrations of AFB1 have been detected in a number of cultivated food products, including wheat, corn, peanuts, fava beans, and both brown and white rise, from various urban and rural districts in Egypt (Hifnawy et al., 2004) , while AFB1 was found in serum and urine of Egyptian infants with protein-energy malnutrition (Hatem et al., 2005) .
From a pathogenic perspective, exposure to AFB1 promotes deoxyribonucleic acid (DNA) damage with generation of characteristic mutations in hepatic tissue, particularly with regard to the p53 tumor suppressor gene, a mutation found in over 50% of AFB1-exposed HCC patients (Betaratinia et al., 2009 ). In addition, chronic infections with hepatitis B or C viruses cause liver damage with development of cirrhosis which, when coupled with the supplemental ability of hepatitis B viral DNA to integrate into the host genome, all contribute to an increased risk of development of HCC (Xiang et al., 2017) .
Detection of HCC while in its initial stages is of paramount importance, as evidenced by a 5-year overall survival (OS) rate exceeding 50% when the disease is detected early compared to less than 10% with late HCC detection associated with poor prognosis as result of metastasis and recurrence (Hung et al., 2016) . Therefore, therapeutic advances regarding HCC metastasis and recurrence are dependent on better comprehension of the elaborate molecular machinery determining disease aggression and evolution, as well as searching for important diagnostic markers and therapeutic targets (Liu et al., 2014) .
Several studies have demonstrated a connection between HCC and the abnormal expression of microRNAs (Lyra-Gonzalez et al., 2015) . MicroRNAs are short, endogenous, non-coding RNAs that coordinate the translation of protein-coding genes by either abolishing translation of target mRNAs or enhancing degradation of mRNA (Vera et al., 2013) , thus regulating gene expression in a quick sensitive manner (Hayes and Chayama, 2016) . MicroRNA disorganization has been implicated in a multitude of disorders, including cancer, through modification of natural cell development and differentiation (Lynam-Lennon et al., 2009) .
The high stability of microRNAs in circulation, added to the fact that microRNA expression patterns appear to be tissue-specific, sets the stage for detection of circulating microRNAs to be potentially used as ideal biomarkers for pre-clinical HCC (Huang et al., 2016) . Several studies have confirmed the ability of serum microRNAs to recognize early-stage HCC caused by infections with hepatitis B and C viruses (Motawi et al., 2015; Wang et al., 2015) . However, very limited data exist correlating serum microRNA expression with HCC caused by AFB1 exposure. Therefore, analysis of microRNAs in circulation of patients with cirrhosis and HCC exposed to AFB1 may offer a clinically applicable non-invasive diagnostic means for detection of curable stages of this malignancy. Amid more than 2000 human microRNAs defined to date, microRNA-24 has been found to modulate the development of cancer in a variety of malignancies, including HCC (Hatziapostolou et al., 2011; Martin et al., 2014) . Therefore, we aimed in this study to assess the role of circulating microRNA-24 expression in patients with cirrhosis and those with HCC who have experienced high levels of AFB1 exposure, in addition to studying the role of AFB1 exposure as an associated risk factor for development of HCC.
Subjects and Methods
This case-control study was conducted on 74 patients with hepatic cirrhosis due to hepatitis C virus (HCV) presented to Mansoura University Hospital during the period from January 2016 until March 2017. Of these, 50 patients had hepatocellular carcinoma and 24 patients were HCC free. In addition, 20 healthy subjects chosen from the blood donors' healthy subjects, were recruited as a control group.
Patients included in the study were those over 18 years of age who were positive for HCV antibodies with cirrhosis or HCC in absence of other known malignancies. Due to its established role as a direct participant in the hepato-carcinogenic process, and to avoid confounding results, patients with HBV were excluded, as were patients with human immunodeficiency virus (HIV). All patients were subjected to thorough clinical, laboratory, and radiological assessment. Cirrhotic patients were diagnosed based on imaging (ultrasound or computerized tomography) findings and characteristic liver function abnormalities, then classified according to Child-Pugh score.
In case of presence of elevated αfetoprotein >400ng/ml, diagnosis of HCC was confirmed with one positive imaging study, such as magnetic resonance imaging (MRI) and/or computerized tomography (CT), while cases with normal α-fetoprotein level required two positive imaging studies (Song and Bae, 2012)
Blood Sampling
Ten milliliters of blood were taken from each participant, which were then divided into three aliquots. One aliquot contained blood over ethylenediaminetetraacetic acid (EDTA) from which plasma was separated for microRNA-24 extraction, while another aliquot was a plain aliquot for sera separation for determination of aflatoxin B1 by immunoassay. Sera separated from the third aliquot were used for laboratory study of complete liver functions by autoanalyzer (Dialab 450 system), determination of circulatory anti-HCV by Elecys system (Roche-diagnostic) and alpha fetoprotein (AFP) measurement by ELISA -DRG International Inc., USA.
AFB1 measurement by ELISA
"The aflatoxin B1 (AFB1) level in serum samples was determined by (Ridascreen-R-Biopharm AG, Demstadt, Germany), an ELISA kit based on competitive enzyme immune assay for the quantitative analysis of aflatoxin B1. Preparation of serum samples required predilution with a dilution buffer" (8.75ml sample buffer of Ridascreen and 1.25ml methanol).
MicroRNA-24 assessment by real-time PCR

MicroRNA isolation
MicroRNA was prepared from 200μl serum samples by the use the microRNA extraction kit (Qiagen) according to the manufacturer's instructions. All isolated microRNAs were aliquoted and stored at −80°C until use.
Complementary DNA (cDNA) synthesis
Reverse transcription (RT) was carried out in a 20μl solution that contained 0.2μl 200U/μl reverse transcriptase (Qiagen), 0.2μl 40U/μl ribonuclease inhibitor, 0.8μl 10mmol/ml dNTP mix, 1.2μl 10mmol/ml stem-loop RT primer, 4μl RT buffer, 11.6μl RNAase-free water and 2μl microRNA template. After gentle mixing, the reaction mixtures were incubated at 25°C for 5 min, 40°C for 60 min and then 70 °C for 15 min. The final cDNA products were stored at −20 °C until use. The reverse transcription primer was miR-24 [GenBank : AF480527.1], 5′-GTCGTATCCAGTGCGTGTCGTGGAGTCG GCAATTGCACTGATACGACCTGTTCCT-3′.
Quantitative real-time PCR
Real-time PCR was carried out following the manufacturer's protocol of SYBR Premix Ex Taq TM II reagents with 2μl cDNA template (Qiagen) (Fang et al., 2015) .
Statistical Analysis
All statistical analyses were performed using statistical package for the social sciences (SPSS) 16.0 (Chicago, IL) and a significance threshold of P<0.05 was used. Continuous data were expressed as mean ± SD and compared between groups using Bonferroni test. Categorical data were analyzed using a twosided Chi-squared test or Fisher's exact test, when appropriately indicated. ROC curve was done to differentiate between groups.
Ethical Approval
Informed consent was taken from each patient. The research protocol was approved by the Ethical Committee of Faculty of Medicine, Mansoura University (proposal code: R.18.02.53).
Results
Demographic data and laboratory parameters of the studied groups are displayed in tables (1) and (2) Aflatoxin B1 levels measured in study subjects are shown in table (4) and figure 1, and were shown to be significantly elevated in all patient groups of cirrhosis (3.7±1.9) and HCC (5.4±2.1) when compared to the control group (1.2±0.4). Similarly, the increased AFB1 level was also found to be statistically significant in the HCC group in comparison to the group with cirrhosis (p<0.0001).
Evaluation of microRNA-24 expression in the different studied groups is demonstrated in table (5) and figure (2). MicroRNA-24 was found to be significantly higher in both HCC (2.6±1.3) and cirrhotic (1.7±1.3) patient groups when compared with controls (0.6±0.3), with this elevation being more prominent in the HCC group than in cirrhotic patients, and in the cirrhotic group more than control individuals (p<0.0001).
Correlation analysis between aflatoxin B1 and microRNA-24 expression in different studied groups showed no correlation between these parameters in the control group of subjects (p<0.755) ( Figure 3 ). However, highly significant correlation was found between the levels of aflatoxin B1 detected in cirrhotic patients and the amount of microRNA-24 expressed in these patients (r=0.933; p<0.0001) ( Figure 4 ), as was detected in HCC patients (r=0.868; p<0.0001) ( Figure 5 ).
ROC curve analysis for microRNA-24 expression demonstrated that at a cutoff of 0.85, microRNA-24 had sensitivity of 80% and specificity of 75% in differentiating cirrhosis from normal liver of control group of subjects ( Figure 6 ), and 98% sensitivity and 85% specificity in delineating HCC from control liver (Figure 7) , both findings were highly significant (p<0.0001). Furthermore, when differentiating between patients with HCC and those with cirrhosis, microRNA-24 demonstrated sensitivity of 80% and specificity of 63% at a cutoff of 1.3, another highly significant finding (p<0.0001) ( Figure 8 ). The p value indicates the statistical significance for the differences among groups. *Significant. WBC: White blood cells, RBC: Red blood cells, HB: Hemoglobin, INR: International normalized ratio, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, Na: Sodium, K: Potassium, AFP: Alfa-fetoprotein, n: number, HCC: Hepatocellular carcinoma. Fig. (1) : Box plots for aflatoxin B1 levels in the different studied groups. HCC: Hepatocellular carcinoma Fig. (2) : Box plots for microRNA-24 expression in the different studied groups. RNA: ribonucleic acid. Fig. (7) 
Discussion
Ingestion of aflatoxins and exposure to hepatitis B or C viruses have been widely established as cardinal risk factors for hepatocarcinogenesis. Aflatoxin B1 (AFB1) is a mycotoxin that originates from some mold species such as Aspergillusparasiticus and Aspergillusflavus that commonly contaminate various harvested products when stored in moist environments. Ingestion of this toxin is followed by its metabolism by cytochrome P450 into aflatoxin B1-exo-8,9 epoxide (AFBO), a toxic metabolite capable of binding to DNA and causing genomic DNA damage, especially in the p53 suppressor gene, with initiation of hepatocellular carcinoma (HCC) development (Xia et al., 2013) . In addition, the end stage of viral hepatitis caused by exposure to HBV or HCV is ultimately liver damage by cirrhosis which, in addition to integration into host genome by hepatitis B viral DNA, collectively contribute to an increased risk of development of HCC (Xiang et al., 2017) .
The association of microRNAs with hepatocellular carcinoma has been a subject of intense analysis in recent years. By organizing gene expression, these small noncoding RNAs are capable of influencing a variety of different cell functions including cell differentiation and proliferation, metabolism, and cell apoptosis (Bartel, 2004) . In addition, their effects on expression of oncogenes and tumor suppressor genes has established their pivotal role in pathogenesis of numerous cancers, including hepato-carcinogenesis (Ranganathan and Sivasankar, 2014; Lu et al., 2016) . The exceptional stability and tissue-specific expression patterns of serum microRNAs have strengthened their role as potential contenders for noninvasive cancer testing (Wu et al., 2017) . On this foundation, serum microRNAs have been proposed to be of potential diagnostic value for HCC, especially that related to high AFB1 exposure. Worthy of mention is the possible involvement of miRNA-24 in carcinogenesis (Han et al., 2012) . Several studies have demonstrated persistent dysregulation of microRNA-24 in patients with hepatocellular carcinoma (Han et al., 2012; Salvi et al., 2013) . Sensitivity: 80% Specificity: 63% AUC: 0.71 (0.58-0.85) P value < 0.001 Cutoff : 1.3 Accordingly, the current case-control study aimed to assess and analyze the diagnostic role of circulating microRNA-24 expression in patients with HCC in comparison to patients with cirrhosis in areas of high AFB1 endemicity such as Egypt as well as to study the role of AFB1 exposure as an associated risk factor for development of HCC.
Aflatoxin B1 levels evaluated in 50 patients with HCC and 24 patients with hepatic cirrhosis included in this study was shown to be significantly elevated in all patient groups when compared to the control group of subjects. In addition, the increased AFB1 level was also found to be statistically significant in the HCC group in comparison to the group with cirrhosis. In similarity to the present study, Sharaf-Eldin et al. (2016) showed that serum aflatoxin levels were significantly increased to a greater extent in HCC patients than cirrhotic patients, and in the latter patients than in controls, possibly ascribed to the accumulative ramifications of prolonged exposure to aflatoxin with advanced age. These results corroborate analogous studies conducted in Egypt demonstrating higher aflatoxin B1 levels in cases of HCC, especially if they were male farmers from rural areas afflicted with chronic HCV and presenting with cirrhosis as well as multifocal HCC lesions. These results support the critical role of aflatoxin B1 in the appearance of HCC (Abdel-Wahab et al., 2008) .
On a similar scale, evaluation of microRNA-24 expression in the different studied groups showed that microRNA-24 was found to be significantly higher in both HCC and cirrhotic patient groups when compared with controls, with this elevation being more prominent in the HCC group than in cirrhotic patients, and in the cirrhotic group more than control individuals. Frequent dysregulation of microRNA-24 expression in liver cancer has been previously demonstrated (Han et al., 2012; Salvi et al., 2013) . In addition, various studies have exposed different expression patterns of serum microRNAs in HCCs when compared to non-HCCs (Wu et al., 2017) , highlighting the ability of serum microRNAs to distinguish HCC cases from controls (Motawi et al., 2015; Zhang et al., 2015; Hung et al., 2016) . Taken together, results of these studies propose that serum microRNAs might be of relevance as noninvasive biomarkers for the diagnosis of HCC.
Therefore, in an attempt to determine the efficacy of microRNA-24 expression in discriminating between HCC, cirrhosis, and control subjects, ROC curve was done for all studied groups. At a cutoff of 0.85, microRNA-24 was found to adequately differentiate cirrhosis from controls with sensitivity of 80% and specificity of 75%, while an even higher sensitivity of 98% and specificity of 85% was demonstrated in discerning HCC from control individuals, both findings being highly significant. Moreover, microRNA-24 was found to differentiate HCC from cirrhosis at a cutoff of 1.3 with sensitivity of 80% and specificity of 63%, also a highly significant finding. Our data indicate that the overexpression of microRNA-24 detected in both our study groups of cirrhosis and HCC might be of use as a noninvasive biomarker delineating cirrhosis from HCC.
Correlation between aflatoxin B1 levels and serum microRNA-24 expression in the current study was insignificant in the control group of study subjects, while both patient groups showed highly significant correlation between these studied variables, more so in HCC patients than in cirrhotic patients. A study by Liu et al. (2014) showed that increased expression of microRNA-24 could advance AFB1-DNA synthesis, possibly as a result of their targeted effect on detoxification enzyme genes (Oda et al., 2012) resulting in diminished detoxification capacity with consequent aggregation of AFB1-DNA (Liu et al., 2014) . Furthermore, other studies showed that low microRNA expression of DNA repair would limit the scope of DNA repair thus increasing the extent of DNA damage and risk of HCC (Long et al., 2013; Huang et al., 2016) . These observations contribute to a unique understanding of the mechanism behind AFB1-induced HCC (Liu et al., 2014) .
In conclusion, our results show that increased aflatoxin B1 levels detected in patients with cirrhosis and HCC further support previous studies evaluating the level of exposure of the Egyptian population to this carcinogen and support the critical role of aflatoxin B1 in the appearance of HCC. In addition, microRNA-24 expression levels demonstrated in both cirrhosis and HCC might be valuable for use as a noninvasive diagnostic tool for diagnosis of HCC. However, further studies into the fundamental role of microRNAs and their dysregulated expression patterns involved in hepatic carcinogenesis will afford valuable insights into the intricate molecular pathogenesis of HCC with possible facilitation of novel therapies for HCC patients, particularly those from areas of high AFB1 exposure. 
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